Saturday, April 20, 2024 4/20/2024

Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling

Award Number: R01AI173328
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Project Summary/Abstract While the emergence of multi-drug resistant tuberculosis raises an urgent need for antimicrobials with new Modes of Action, their discovery remains a major challenge. Many of the techniques to unravel drug Modes of Action rely on low-throughput, time-consuming and target-specific approaches that provide low- dimensional views into the broader functional impact of potential drugs. Together with the Zampieri lab at ETH Zurich, Switzerland, by leveraging CRISPR technology and non-targeted metabolomics, we developed a combined computational/experimental strategy that is based on the comparison of genetic and drug induced metabolic effects and allows to perform high-throughput de novo functional annotations of large compound libraries. Unraveling the mechanistic basis of drug or gene perturbations of thousands of metabolites provides rich multidimensional information complementary to classical phenotypic profiling and can be used to investigate the effect and mode of action of any drug candidate. The overall goal of the present proposal is to achieve functional annotation of 500 anti-TB compounds with known potency but unknown MoA, which will pave the way to new unconventional strategies to eradicate TB. We will build a compendium of metabolic responses of Mtb to essential gene knockdown, transcription factor overexpression and a unique selection of libraries of Mtb growth inhibitors. We will use our custom- developed computational tools to categorize drug action and gene knockdowns according to metabolic profiles, make testable hypothesis about unconventional drug MoA and move prioritized compounds to genetic and biochemical hit validation. An important collateral benefit of our proposed work will be functional annotation of genes with yet unknown function in M. tuberculosis, and an information dense database on gene-drug-metabolic interactions in M. tuberculosis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $573,131 )
2024	2024	ALBERT EINSTEIN COLLEGE OF MEDICINE	1300 MORRIS PARK AVE	BRONX	NY	10461	BRONX	USA	Allergy and Infectious Diseases Research	000	2	10/25/2023	NON-COMPETING CONTINUATION	$573,131
														Subtotal = $573,131

Issue Date FY: 2023 ( Subtotal = $653,812 )
2023	2023	ALBERT EINSTEIN COLLEGE OF MEDICINE	1300 MORRIS PARK AVE	BRONX	NY	10461	BRONX	USA	Allergy and Infectious Diseases Research	000	1	11/18/2022	NEW	$653,812
2023	2023	ALBERT EINSTEIN COLLEGE OF MEDICINE	1300 MORRIS PARK AVE	BRONX	NY	10461	BRONX	USA	Allergy and Infectious Diseases Research	001	1	2/21/2023	NEW	$0
														Subtotal = $653,812

Grand Total All Awards = $1,226,943

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling

Award Number: R01AI173328

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer